Higher miR-21 expression in invasive breast carcinomas is associated with positive estrogen and progesterone receptor status in patients from Serbia

Medical Oncology

Volumn 31, Issue 6, 2014, Pages

  Petrović, Nina ^a   Mandušić, Vesna ^a   Dimitrijević, Bogomir ^a   Roganović, Jelena ^b   Lukić, Silvana ^c   Todorović, Lidija ^a   Stanojević, Boban ^a  

^a UNIVERSITY OF BELGRADE   (Serbia)

^b UNIVERSITY OF BELGRADE   (Serbia)

^c INSTITUTE FOR ONCOLOGY AND RADIOLOGY OF SERBIA   (Serbia)

Author keywords

Estrogen receptor status; Invasive breast carcinoma; Micro RNA; MiR 21 expression levels; Progesterone receptor status

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; KI 67 ANTIGEN; MICRORNA 21; PROGESTERONE RECEPTOR; ERBB2 PROTEIN, HUMAN; MICRORNA; MIRN21 MICRORNA, HUMAN;

ADULT; ARTICLE; BREAST CARCINOMA; CANCER GRADING; CANCER HORMONE THERAPY; CANCER PATIENT; CELL PROLIFERATION; CLINICAL ARTICLE; CONTROLLED STUDY; GENE EXPRESSION; GENETIC ASSOCIATION; GROUPS BY AGE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; PRIORITY JOURNAL; REAL TIME POLYMERASE CHAIN REACTION; SERBIA; TREATMENT FAILURE; TUMOR VOLUME; AGED; BREAST TUMOR; FEMALE; GENETICS; LUNG CARCINOMA; METABOLISM; MIDDLE AGED; PAGET NIPPLE DISEASE; PATHOLOGY; REFERENCE VALUE;

AGED; BREAST NEOPLASMS; CARCINOMA, DUCTAL, BREAST; CARCINOMA, LOBULAR; FEMALE; HUMANS; MICRORNAS; MIDDLE AGED; RECEPTOR, ERBB-2; RECEPTORS, ESTROGEN; RECEPTORS, PROGESTERONE; REFERENCE VALUES; SERBIA;

EID: 84901738320     PISSN: 13570560     EISSN: 1559131X     Source Type: Journal    
DOI: 10.1007/s12032-014-0977-5     Document Type: Article

References (31)

1. Pan X, Wang Z-X, Wang R. MicroRNA-21: a novel therapeutic target in human cancer. Cancer Biol Ther. 2010;10(12):1224-32. doi:10.4161/cbt.10.12.14252.
2. Shenouda SK, Alahari SK. MicroRNA function in cancer: oncogene or a tumor suppressor? Cancer Metast Rev. 2009;28(3-4):369-78. doi:10.1007/s10555-009- 9188-5.
3. Huang G-L, Zhang X-H, Guo G-L, Huang K-T, Yang K-Y, Shen X, You J, Hu X-Q. Clinical significance of miR-21 expression in breast cancer: SYBR-Green I-based real-time RT-PCR study of invasive ductal carcinoma. Oncol Rep. 2009. doi:10.3892/or- 00000270.
4. Song B, Wang C, Liu J, Wang X, Lv L, Wei L, Xie L, Zheng Y, Song X. MicroRNA-21 regulates breast cancer invasion partly by targeting tissue inhibitor of metalloproteinase 3 expression. J Exp Clin Cancer Res. 2010;29(1):29. doi:10.1186/1756-9966-29-29.
5. Lee JA, Lee HY, Lee ES, Kim I, Bae JW. Prognostic implications of MicroRNA-21 overexpression in invasive ductal carcinomas of the breast. Int J Breast Cancer. 2011;14(4):269-75. doi:10.4048/jbc.2011.14.4.269.
6. Qi L, Bart J, Tan L, Platteel I, Sluis T, Huitema S, Harms G, Fu L, Hollema H, Berg A. Expression of miR-21 and its targets (PTEN, PDCD4, TM1) in flat epithelial atypia of the breast in relation to ductal carcinoma in situ and invasive carcinoma. BMC Cancer. 2009;9(1):163. doi:10.1186/1471-2407-9-163.
7. Yoshinaga H, Matsuhashi S, Fujiyama C, Masaki Z. Novel human PDCD4 (H731) gene expressed in proliferative cells is expressed in the small duct epithelial cells of the breast as revealed by an anti-H731 antibody. Pathol Int. 1999;49:1067-77. doi:10.1186/bcr1285. (Pubitemid 30193505)
8. Yang Y, Chaerkady R, Beer MA, Mendell JT, Pandey A. Identification of miR-21 targets in breast cancer cells using a quantitative proteomic approach. Proteomics. 2009;9(5):1374-84. doi:10.1002/pmic.200800551.
9. Span PN, Lindberg RLP, Manders P, Tjan-Heijnen VCG, Heuvel JJTM, Beex LVAM, et al. Tissue inhibitors of metalloproteinase expression in human breast cancer: TIMP-3 is associated with adjuvant endocrine therapy success. J Pathol. 2004;202(4):395-402. doi:10.1002/path.1528. (Pubitemid 38456157)
10. Mylona E, Magkou C, Giannopoulou I, Agrogiannis G, Markaki S, Keramopoulos A, Nakopoulou L. Expression of tissue inhibitor of matrix metalloproteinases (TIMP)-3 protein in invasive breast carcinoma: Relation to tumor phenotype and clinical outcome. Breast Cancer Res. 2006;8(5):R57. doi:10.1186/bcr1607.
11. Li J, Zhang Y, Zhang W, Jia S, Tian R, Kang Y, Ma Y, Li D. Genetic heterogeneity of breast cancer metastasis may be related to miR-21 regulation of TIMP-3 in translation. Int J Sur Oncol. 2013;2013:1-7. doi:10.1155/2013/875078.
12. Zhu S, Si ML, Wu H, Mo YY. MicroRNA-21 targets the tumor suppressor gene tropomyosin 1 (TPM1). J Biol Chem. 2007;282(19):14328-36. doi:10.1074/jbc. M611393200. (Pubitemid 47100416)
13. Lopez-Camarillo C, Fonseca-SánchezMA, Flores-Pérez A, Marchat LA, Arechaga-Ocampo E, Azuara-Liceaga E, et al. Functional roles of microRNAs in cancer: microRNomes and oncomiRs connection. In: Lopez-Camarillo C, Marchat LA, Arechaga-Ocampo E, Azuara- Liceaga E, Perez Plasencia C, Fuentes-Mera L, et al., editors. Oncogenomics and cancer proteomics-novel approaches in biomarkers discovery and therapeutic targets in cancer. InTech, p. 72-89, 2013; 9(1):53-9. doi:10.1111/j.1743-7563.2012.01548.x.
14. Rask L, Balslev EVA, Jørgensen S, Eriksen J, Flyger H, MØLler S, HØGdall E, Litman T, Schnack Nielsen B. High expression of miR-21 in tumor stroma correlates with increased cancer cell proliferation in human breast cancer. Apmis. 2011;119(10):663-73. doi:10.1111/j.1600-0463.2011. 02782.x.
15. Esquela-Kerscher A, Slack FJ. Oncomirs-microRNAs with a role in cancer. Nat Rev Cancer. 2006;6(4):259-69. doi:10.1038/nrc1840.
16. Schwarz DS, Hutvagner G, Du T, Xu Z, Aronin N, Zamore PD. Asymmetry in the assembly of the RNAi enzyme complex. Cell. 2003;115(2):199-208. (Pubitemid 37329583)
17. Lowery AJ, Miller N, Devaney A, McNeill RE, Davoren PA, Lemetre C, Benes V, Schmidt S, Blake J, Ball G, Kerin MJ. MicroRNA signatures predict oestrogen receptor, progesterone receptor and HER2/neu receptor status in breast cancer. Breast Cancer Res. 2009;11(3):R27. doi:10.1186/bcr2257.
18. Verkooijen HM, Fioretta Gr, Vlastos G, Morabia A, Schubert H, Sappino A-P, et al. Important increase of invasive lobular breast cancer incidence in Geneva, Switzerland. Int Cancer. 2003;104(6):778-81. doi:10.1002/ijc.11032.
19. Petrović N, Mandušić V, Stanojević B, Lukić S, Todorović L, Roganović J, et al. The difference in miR-21 expression levels between invasive and non-invasive breast cancers emphasizes its role in breast cancer invasion. Med Oncol. 2014;31(3):867. doi:10.1007/s12032-014-0867-x.
20. Harrell JC, Dye WW, Harvell DM, Pinto M, Jedlicka P, Sartorius CA, Horwitz KB. Estrogen insensitivity in a model of estrogen receptor positive breast cancer lymph node metastasis. Cancer Res. 2007;67(21):10582-91. (Pubitemid 350070835)
21. Yamashita H, Nishio M, Kobayashi S, Ando Y, Sugiura H, Zhang Z, Hamaguchi M, Mita K, Fujii Y, Iwase H. Phosphorylation of estrogen receptor a serine 167 is predictive of response to endocrine therapy and increases postrelapse survival in metastatic breast cancer. Breast Cancer Res. 2005;7(5):R753. doi:10.1186/ bcr1285.
22. Ng CH, Pathy NB, Taib NA, Mun KS, Rhodes A, Yip CH. The estrogen receptor negative-progesterone receptor positive breast carcinoma is a biological entity and not a technical artifact. Asian Pac J Cancer Prev. 2012;13(4):1111-3. doi:10.7314/apjcp.2012.13.4.1111.
23. Leake R. Immunohistochemical detection of steroid receptors in breast cancer: a working protocol. J Clin Pathol. 2000;53(8):634-5. doi:10.1136/jcp.53.8.634. (Pubitemid 30640178)
24. Sauter G, Lee J, Bartlett JMS, Slamon DJ, Press MF. Guidelines for human epidermal growth factor receptor 2 testing: biologic and methodologic considerations. J Clin Oncol. 2009;27(8):1323-33. doi:10.1200/jco.2007.14.8197.
25. Kim YJ, Hwang SJ, Bae YC, Jung JS. miR-21 regulates adipogenic differentiation through the modulation of TGF-b signaling in mesenchymal stem cells derived from human adipose tissue. Stem Cells. 2009;27(12):3093-102. doi:10.1002/stem.235.
26. Qian B, Katsaros D, Lu L, Preti M, Durando A, Arisio R, Mu L, Yu H. High miR-21 expression in breast cancer associated with poor disease-free survival in early stage disease and high TGFb1. Breast Cancer Res Treat. 2008;117(1):131-40. doi:10.1007/ s10549-008-0219-7.
27. Wickramasinghe NS, Manavalan TT, Dougherty SM, Riggs KA, Li Y, Klinge CM. Estradiol downregulates miR-21 expression and increases miR-21 target gene expression in MCF-7 breast cancer cells. Nucl Acids Res. 2009;37(8):2584-95. doi:10.1093/nar/gkp117.
28. Iorio MV, Ferracin M, Liu CG, Veronese A, Spizzo R, Sabbioni S, Magri E, Pedriali M, Fabbri M, Campiglio M, Menard S, Palazzo JP, Rosenberg A, Musiani P, Volinia S, Nenci I, Calin GA, Querzoli P, Negrini M, Croce CM. MicroRNA gene expression deregulation in human breast cancer. Cancer Res. 2005;65(16):7065-70. doi:10.1158/0008-5472.CAN-05-1783. (Pubitemid 41161233)
29. Huang TH, Wu F, Loeb GB, Hsu R, Heidersbach A, Brincat A, Horiuchi D, Lebbink RJ, Mo YY, Goga A, McManus MT. Upregulation of miR-21 by HER2/neu signaling promotes cell invasion. J Biol Chem. 2009;284(27):18515-24. doi:10.1074/jbc.M109.006676.
30. Mattie MD, Benz CC, Bowers J, Sensinger K, Wong L, Scott GK, Fedele V, Ginzinger D, Getts R, Haqq C. Optimized highthroughput microRNA expression profiling provides novel biomarker assessment of clinical prostate and breast cancer biopsies. Mol Cancer. 2006;5(1):24. doi:10.1186/1476-4598-5-24.
31. Arpino G, Weiss H, Lee AV, Schiff R, De Placido S, Osborne CK, Elledge RM. Estrogen receptor-positive, progesterone receptor-negative breast cancer: association with growth factor receptor expression and tamoxifen resistance. J Nat Cancer Inst. 2005;97(17):1254-61. doi:10.1093/jnci/dji249. (Pubitemid 41535366)